Clinical Report: Immunometabolic Insights into MASH Pathogenesis and Immune Cell Roles
Overview
Metabolic dysfunction-associated steatohepatitis (MASH) is a complex immunometabolic disorder where immune cells play a central role in disease progression. Immune dysregulation and metabolic dysfunction form a self-perpetuating cycle, making immune modulation a critical therapeutic target.
Background
MASH, formerly known as nonalcoholic steatohepatitis (NASH), is an inflammatory stage of metabolic dysfunction-associated steatotic liver disease (MASLD) and represents a major global health burden. It affects up to 38% of adults worldwide, with progression from steatosis to MASH occurring in 10% to 30% of patients. The disease exhibits heterogeneity, with both obese and lean individuals affected, challenging the traditional metabolic-centric view. Recent evidence highlights the liver’s diverse immune cell populations and their dynamic role in modulating inflammation and tissue repair in MASH.
Data Highlights
Up to 38% of adults worldwide are affected by MASLD, with 10% to 30% progressing to MASH. Approximately 19% of MASH patients are lean, and 40% are non-obese, indicating heterogeneity in disease manifestation. Cytokines such as IL-1, IL-6, and TNF-α contribute to systemic inflammation and insulin resistance in MASH pathogenesis.
Key Findings
MASH pathogenesis involves a bidirectional interaction between metabolic dysfunction and immune dysregulation, forming a self-perpetuating pathogenic circuit.
The liver harbors a diverse population of resident immune cells, including myeloid and lymphoid subsets, which can either sustain inflammation or promote tissue repair.
Immune cell metabolic reprogramming occurs in response to the hepatic microenvironment, influencing disease progression or remission.
Systemic factors such as adipose tissue inflammation and cytokine secretion (IL-1, IL-6, TNF-α) contribute to hepatic metabolic stress and immune activation.
Current therapies focusing solely on weight loss may overlook direct immunomodulatory effects that contribute to treatment efficacy.
Recognizing MASH as an immunometabolic disorder supports integrating metabolic and immune-targeted strategies for effective management.
Clinical Implications
Clinicians should consider immune dysregulation as a primary driver in MASH progression, not merely a secondary consequence of metabolic dysfunction. Therapeutic approaches that combine metabolic control with immune modulation may improve patient outcomes. Understanding the hepatic immune landscape is essential for developing targeted interventions beyond weight reduction.
Conclusion
MASH is fundamentally an immunometabolic disorder where immune cells critically influence disease trajectory. Integrating immunological insights with metabolic management offers a promising avenue for advancing MASH treatment.
